



55th INPC

PULA 2015

**55th International
Neuropsychiatric
Congress**

May 27-30, 2015 Pula, Croatia



www.pula-cong.com

South East European Society for Neurology and Psychiatry
INTERNATIONAL NEUROPSYCHIATRIC PULA CONGRESS
KURATORIUM

SECRETARY GENERAL: Vida Demarin, Zagreb

HONORARY PRESIDENT: Boško Barac, Zagreb

FOUNDING HONORARY MEMBERS

H. Bertha, Graz	G. Grinschgl, Graz	P. Kartin, Ljubljana	H. Lechner, Graz
R. Lopašić, Zagreb	F. Marguth, München	N. Peršić, Zagreb	J. Ristić, Beograd
A. Rosenzweig, Zagreb	W. Scheid, Köln	O. Stochdorf, München	G. Huber, Bonn

HONORARY MEMBERS

D. Fontanari, Venezia	F. Gerstenbrand, Vienna	G. Lanner, Klagenfurt	J. Kugler, München
V. Muačević, Zagreb	B. Neundörfer, Erlangen	C. M. Poser, Boston	A. Stammeler, Köln

BOARD OF TRUSTEES

B. Barac, Zagreb	L. Battistin, Padova	K. Bechter, Günzburg	F. Benedetti, Milan
A. Czlonkowska, Warsaw	A. Danilov, Russia	V. Demarin, Zagreb	V. Đorđević, Zagreb
V. Folnegović-Šmalc, Zagreb	V. Jukić, Zagreb	H. P. Kapfhammer, Graz	G. E. Klein, Graz
V. Kostić, Beograd	E. S. Koutsouraki, Thessaloniki	Z. Lacković, Zagreb	S. Loga, Sarajevo
Đ. Ljubičić, Rijeka	N. Müller, München	K. Niederkorn, Graz	E. Ott, Graz
T. Pogačnik, Ljubljana	T. S. Prevec, Ljubljana	M. Relja, Zagreb	O. Sinanović, Tuzla
B. Tsygankov, Russia	V. Šerić, Zagreb	Z. Trkanjec, Zagreb	E. Uhl, Klagenfurt
L. Vécsei, Szeged	D. B. Vodusek, Ljubljana		

SCIENTIFIC ADVISORY BOARD

A. Alajbegović, Sarajevo	Z. Ambler, Pilsen	S. Butković Soldo, Osijek	C. Carollo, Padova
R. Erkwow, Erfurt	R. Fahlbusch, Erlangen	H. Katschnig, Wien	J. Klosterkötter, Köln
M. Kocmur, Ljubljana	R. Ljubičić, Zagreb	H. Sass, Aachen	W. K. Tang, Hong Kong
L. Toresini, Portogruaro	L. Tuškan-Mohar, Rijeka	M. Wender, Poznan	

LOCAL ORGANIZING COMMITTEE

D. Breški, Pula	D. Janko Labinac, Pula	D. Marković, Pula	I. Šain, Pula
L. Peteh Labinac, Pula	L. Radolović-Prenc, Pula	F. I. Silconi, Pula	

Secretary General: **Vida Demarin, MD, PhD, FAAN, FAHA, FESO**, Fellow of Croatian Academy of Sciences and Arts, Professor of Neurology, Medical center Aviva, Nemetova 2, HR-10000 Zagreb, Croatia
E-mail: vida.demarin@zg.t-com.hr

INPC Office in Graz: **Kurt Niederkorn, MD, Ph.D.** Univ. Professor of Neurology, Neurologische Universitätsklinik, Auenbruggerplatz 22, A-8036 Graz, Austria; Phone: +43 316 385 83245; Fax +43 316 385 3512;
E-mail: kurt.niederkorn@medunigraz.at

Alps Adria Office: **Leontino Battistin, MD, Ph.D.** Professor of Neurology, Dept of Neurology, University of Padova, Via Giustiniani 5, 35128 Padova, Italy • Phone: +39 049 821 36 00 Fax: +39 049 875 17 70
E-mail: segr.neurologia@unipd.it

Honorary President: **Boško Barac, MD, Ph.D.** Professor of Neurology (ret), Schools of Medicine, Universities of Zagreb and Osijek. Pantovčak 102, HR-10000 Zagreb, Croatia • Phone & Fax: +385 1 48 222 97 • E-mail: bosko.barac@gmail.com



*This meeting is endorsed by the World Federation of Neurology
and European Academy of Neurology.*



The 55th International Neuropsychiatric Congress in Pula
under the High Patronage of the President of Republic of Croatia

Her Excellency Mrs. **Kolinda Grabar-Kitarović**

Organizer

SOCIETY FOR NEUROPSYCHIATRY

Coorganizers

DEPARTMENT OF MEDICAL SCIENCES – CROATIAN ACADEMY OF SCIENCES AND ARTS
CENTRAL AND EASTERN EUROPEAN STROKE SOCIETY

Supporting organizations

WORLD FEDERATION OF NEUROLOGY
EUROPEAN ACADEMY OF NEUROLOGY
WFN, APPLIED RESEARCH GROUP
ON THE ORGANISATION AND DELIVERY OF CARE
EUROPEAN PSYCHIATRIC ASSOCIATION
CROATIAN STROKE SOCIETY

Venue

Hotel "Park Plaza Histria" – Pula, Croatia

PROGRAM 55th International Neuropsychiatric Congress

Wednesday, May 27th

- 16:00 – 16:30 **STRESS MANAGEMENT**
Belica Alexey Danilov (Moscow, Russia)
- 16:30 – 18:30 **8th INTERNATIONAL EPILEPSY SYMPOSIUM IN PULA
 “EPILEPSY AND COGNITION”**
Belica *Chairperson:* Hrvoje Hećimović (Zagreb, Croatia)
- AURA IN EPILEPSY
 Hrvoje Hećimović (Zagreb, Croatia)
- FUNCTIONAL STUDIES USING PET/CT IMAGING - WHAT DO THEY TELL US?
 Sunčana Divošević (Zagreb, Croatia)
- 18:30 – 19:30 **ACADEMIC LECTURE - WFN THE WAY AHEAD**
Ulika Raad Shakir, President of the World Federation of Neurology
- 19:30 – 20:30 *Welcoming drink and traditional Istrian folk dances
 performed by Artistic group “Mendula” from Medulin*

Thursday, May 28th

- 09:00 – 10:00 Opening ceremony
Ulika
- MAIN THEME – HIGHLIGHTS IN NEUROLOGY AND PSYCHIATRY
 WHAT HAVE WE LEARNED IN THE LAST 55 YEARS IN:**
- 10:00 – 11:30 *Chairpersons:* Vida Demarin (Zagreb, Croatia), Kurt Niederkorn (Graz, Austria)
- STROKE
 Kurt Niederkorn (Graz, Austria)
- POSTSTROKE DEPRESSION
 Wai Kwong Tang (Hong Kong, China)
- HEADACHE AND PAIN
 Vida Demarin (Zagreb, Croatia)
- 11:30 – 12:00 *Break*
- 12:00 – 13:30 *Chairpersons:* Vesna Šerić (Zagreb, Croatia), Franz Fazekas (Graz, Austria)
- MULTIPLE SCLEROSIS
 Franz Fazekas (Graz, Austria)

- EPILEPSY
 Francesco Paladin (Venice, Italy)
- NEW VISTAS IN NEUROREHABILITATION
 Vesna Šerić (Zagreb, Croatia)

13:30 – 14:30 *Break*

- 14:30 – 16:00 **CONTROVERSIES AND NEWS IN PSYCHIATRY**
Chairpersons: Francesco Benedetti (Milano, Italy), Martin Brüne (Bochum, Germany)

- CLASSIFICATION OF FIRST-EPISODE PSYCHOSIS
 Paolo Brambilla (Udine, Italy)
- NEW FINDINGS ON THE MILD ENCEPHALITIS HYPOTHESIS OF SEVERE MENTAL ILLNESS
 Karl Bechter (Günzburg, Germany)
- THE PROFILE OF SERUM IMMUNE AND GROWTH FACTORS IN RELATION TO NEUROIMAGING
 Francesco Benedetti (Milano, Italy)

16:00 – 16:30 *Break*

- 16:30 – 18:00 **EVOLUTIONARY PERSPECTIVES IN PSYCHOPATHOLOGY**
Chairpersons: Karl Bechter (Günzburg, Germany), Norbert Müller (München, Germany)

- BORDERLINE PERSONALITY DISORDER: INSIGHTS FROM LIFE HISTORY THEORY
 Martin Brüne (Bochum, Germany)
- PSYCHIATRIC CONDITIONS IN CROSS-CULTURAL PERSPECTIVE
 Wulf Schiefenhövel (Andechs, Germany)
- THERAPEUTIC IMPLICATIONS FROM EVOLUTIONARY PSYCHIATRIC INSIGHTS
 Alfonso Troisi (Roma, Italy)

Friday, May 29th

- 09:00 – 10:30 **4th SYMPOSIUM ON INTERFACE PROVIDERS IN NEUROREHABILITATION**
Ulika *Chairpersons:* Raphael Béné (Zagreb, Croatia), Natko Beck (Zagreb, Croatia)
- TRACKING AND REWIRING THE RIGHT NEURAL NETWORKS IN NEUROREHABILITATION
 Raphael Béné (Zagreb, Croatia)
- AFFECTIVE REACTIONS: WHAT CAN BE RECORDED?
 Siniša Popović (Zagreb, Croatia)
- WHAT TECHNOLOGY CAN OFFER TO NEUROREHABILITATION-NEW VISTAS
 Natko Beck (Zagreb, Croatia)
- AUTISM: INSIGHTS INTO NEW COMMUNICATION NETWORKS
 Goran Đingulašević (Zagreb, Croatia)

10:30 – 11:00 Ulrika	SPECIAL LECTURE WILSON'S DISEASE Anna Czlonkowska (Warsaw, Poland)
11:00 – 12:00 Ulrika	Satellite Symposium sponsored by Medis Tecfidera – new option in the treatment of Multiple Sclerosis
12:00 – 13:00 Bianca Istriana	POSTER SESSION - Psychiatry <i>Chairpersons:</i> Karl Bechter (Günzburg, Germany), Francesco Benedetti (Milano, Italy), Johannes Schröder (Heidelberg, Germany)
13:00 – 14:00	Break
14:00 – 15:00 Ulrika	Joint meeting with Central and Eastern European Stroke Society and WFN Applied Research Group on the Organisation and Delivery of Care CURRENT STATUS OF STROKE MANAGEMENT IN THE REGION <i>Chairpersons:</i> Vida Demarin (Zagreb, Croatia), Hrvoje Budinčević (Zagreb, Croatia) STROKE NEUROLOGY IN MEDITERRANEAN COUNTRIES Vida Demarin (Zagreb, Croatia) MANAGEMENT OF STROKE IN CENTRAL AND EASTERN EUROPEAN COUNTRIES Hrvoje Budinčević (Zagreb, Croatia) Discussion: Similarities and Differences
15:00 – 16:30 Ulrika	ACUTE STROKE TREATMENT <i>Chairperson:</i> Kurt Niederkorn (Graz, Austria) INTRAVENOUS THROMBOLYSIS Thomas Gatttringer (Graz, Austria) MECHANICAL THROMBECTOMY Hannes Deutschmann (Graz, Austria) CERVICOCRANIAL DISSECTION Günther Erich Klein (Graz, Austria)
16:30 – 18:00 Ulrika	SYMPOSIUM OF THE ASSOCIATION OF PEOPLE'S HEALTH „ANDRIJA ŠTAMPAR“ HEALTHY LOVE AS A PREREQUISITE OF HEALTH Ivan Vukoja (Požega, Croatia) THE 6 YEARS OF ASSOCIATION'S PUBLIC HEALTH ACTIVITIES Jakov Ivković (Zagreb, Croatia) BE COOL, DON'T BE A BULLY – PRESENTATION OF A PROJECT Maksimilijan Mrak (Zagreb, Croatia), Romano Antunović (Zagreb, Croatia)

	HEALTH FOR ALL - PRESENTATION OF A PROJECT Ana Asančaić (Požega, Croatia)
16:30 – 18:00	POSTER SESSION - Neurology <i>Chairpersons:</i> Kurt Niederkorn (Graz, Austria), Vesna Šerić (Zagreb, Croatia), Zlatko Trkanjec (Zagreb, Croatia)
18:00 – 19:00	Kuratorium meeting
20:00	Farewell cocktail - Istrian eno-gastronomy evening

Saturday, May 30th

08:30 – 09:30	BEST POSTERS AWARDS PRESENTATIONS
09:30 – 13:00	Joint Meeting with Alps-Adria Neuroscience Section, WFN Applied Research Group on the Organisation and Delivery of Care and Central and Eastern European Stroke Society <i>Chairpersons:</i> Leontino Battistin (Padova, Italy), Vida Demarin (Zagreb, Croatia) DISEASE COURSE MODIFICATION IN PARKINSON'S DISEASE Amos Korczyn (Tel Aviv, Israel) BIOMARKERS IN CEREBROSPINAL FLUID (TAU, PHOSPHO-TAU (181) AND NEUROFILAMENT LIGHT) IN CLINICALLY ISOLATED SYNDROME CONVERTED TO MULTIPLE SCLEROSIS Euphrosyni Koutsouraki (Thessaloniki, Greece) ENHANCEMENT OF MOTOR ABILITIES IN PARKINSON'S DISEASE PATIENTS Vladimira Vuletić (Zagreb, Croatia) CHRONIC PELVIC PAIN - EVIDENCE BASED PHARMACOTHERAPY Oleg Davidov (Moscow, Russia) PATIENTS WITH MIGRAINE: A SUBJECTIVE APPROACH WITH QUALITATIVE STUDIES Marjan Zaletel (Ljubljana, Slovenia) THE CLINICAL OUTCOME IMPROVEMENT RATE WITH ENDOVASCULAR THERAPY IN PATIENTS WITH ACUTE STROKE – OUR EXPERIENCES Bojana Žvan (Ljubljana, Slovenia) SMALL ARTERY DISEASE AND COGNITIVE IMPAIRMENT Nadežda Čovičković-Šternić (Belgrade, Serbia) NON-MOTOR STROKE SIGNS AND SYMPTOMS Osman Sinanović (Tuzla, Bosnia and Herzegovina)

CHALLENGING CHILD AND ADOLESCENT IN MODERN SOCIETY

Bianchera hall

Friday, May 29th



09:00 – 10:00 REFLECTION OF CHANGES IN FAMILY RELATIONSHIPS ON THE CHILD'S MENTAL STATUS AND THERAPY SUCCESS
Dubravka Kocijan Hercigonja (Zagreb, Croatia)

RECENT CHANGES IN EARLY BEHAVIORAL FEEDING PROBLEMS AND FAMILY DYNAMICS
Mara Vukadin (Zagreb, Croatia)

INFLUENCE OF MODERN TECHNOLOGIES AND SOCIAL NETWORKS ON PEER RELATIONSHIPS IN ADOLESCENCE
Mihaela Rister Zec (Zagreb, Croatia)

10:00 – 10:20 Discussion

10:20 – 10:40 *Break*

10:40 – 11:40 NONSPECIFIC CLINICAL PICTURE OF DEVELOPMENTAL DISORDERS IN CHILDREN DIAGNOSTIC PROBLEM
Dina Koren (Zagreb, Croatia)

RECENT CHANGES AND CHALLENGES OF DIAGNOSTICS AND TREATMENT IN CHILD AND ADOLESCENT PSYCHIATRY POLICLINIC
Tihana Koren (Zagreb, Croatia)

WHEN FEELING HURTS – INFLUENCE OF ABUSE AND NEGLECT ON DEVELOPING BRAIN
Vanja Slijepčević Saftić (Zagreb, Croatia)

INTENTIONAL DRUG POISONING IN MINORS: RISK FACTORS
Nenad Jakušić (Zagreb, Croatia)

EFFECTS OF CHILDHOOD TRAUMA ON DEVELOPMENTAL PROCESSES
Mirjana Graovac (Rijeka, Croatia)

11:40 – 12:00 Discussion

12:00 – 13:30 *Break*

- 13:30 – 14:30 RESTLESS, IMPULSIVE AND IRRITABLE CHILD-DIFFERENTIAL DIAGNOSIS AND TREATMENT
Nikolina Antonia Domokuš (Popovača, Croatia)
- CHILDHOOD AND ADOLESCENT DEPRESSION – DISORDER WITH MANY DIFFERENT FACES
Nela Ercegović (Zagreb, Croatia)
- CHARACTERISTICS OF DELIBERATE POISONING IN MINORS
Nenad Jakušić (Zagreb, Croatia)
- 14:30 – 15:00 Discussion
- 15:00 – 16:00 **Break**
- 16:00 – 18:00 **ROUND TABLE**
THE EFFICIENCY OF THE PRESENT AND THE NEED FOR NEW THERAPEUTIC APPROACHES IN CHILD AND ADOLESCENT PSYCHOTHERAPY
- Debate questions:
- Qualifications of experts for therapy
 - Multidisciplinary and cooperation
 - What therapeutic approaches should include?
 - Therapeutic work coordinated with European standards (education)
- MODERATOR: Prof. dr. sc. Dubravka Kocijan Hercigonja
- Participants:
- Prof. dr. sc. Dubravka Kocijan Hercigonja
 - Dr. Mirjana Graovac
 - Dr. Nenad Jakušić
 - Tihana Koren, prof. psihologije
 - Dr. Nela Ercegović
 - Dina Koren, prof. soc. ped.



4th EUROPEAN PSYCHOPATHOLOGY SUMMER SCHOOL

Taverna hall

Chairpersons: Karl Bechter, Francesco Benedetti, Martin Brüne

Friday, May 29th

08:30 – 10:00

INTERACTIVE COURSE SESSIONS

Chairpersons: Martin Brüne (Bochum, Germany), Karl Bechter (Günzburg, Germany)

POSSIBLE ROLES OF OXYTOCIN ON EXAPTATION AND MIS-EXAPTATION OF THE INNER SPEECH VIA ITS ACTIONS ON D2R RECOGNITION/DECODING PROCESSES IN NEURONS AND ASTROCYTES

Luigi Agnati (Modena, Italy)

ETHICAL IMPLICATIONS OF THE MILD ENCEPHALITIS HYPOTHESIS

Sabine Müller (Berlin, Germany)

10:00 – 14:00

Break

14:00 – 15:30

Chairpersons: Francesco Benedetti (Milano, Italy), Antonio Vita (Brescia, Italy)

META-ANALYSIS AND META-REGRESSION OF BRAIN IMAGING DATA IN SCHIZOPHRENIA
Antonio Vita (Brescia, Italy)

INFLAMMATION IN ALZHEIMER'S DISEASE: A LECTURE ON THE OCCASION OF THE 100. OBIT OF ALOIS ALZHEIMER

Norbert Müller (Münich, Germany)

2 short presentations selected from submissions by course participants

15:30 – 16:00

Break

16:00 – 17:30

Chairpersons: Francesco Benedetti (Milano, Italy), Paolo Brambilla (Udine, Italy)

YOUNG RESEARCHER SYMPOSIUM:

6 short presentations selected from submissions by course participants

Saturday, May 30th

09:00 – 10:30

INTERACTIVE WORKSHOP WITH CASE VIDEOS AND NEUROPSYCHOLOGICAL TESTING

Chairperson: Johannes Schröder (Heidelberg, Germany)

Mild cognitive impairment (MCI) is generally considered to represent the preclinical phase of Alzheimer's disease (AD). The aim of the present workshop is discuss the diagnostic work up and treatment concepts with reference to typical clinical cases. This will also include differential diagnosis, neuropsychological testing and important biomarkers.

10:30 – 11:00

Break

11:00 – 12:00

PILOT SESSION CASE SUPERVISION

Chairpersons: Karl Bechter (Günzburg, Germany), Johannes Schröder (Heidelberg, Germany)

Participants can present own cases (speaking, paper or video) and pose specific questions to be discussed with the group and the supervisors.



Under the patronage of EPA.

INTERNATIONAL SPORTS PSYCHIATRY MEETING

Belica hall

Chairpersons: Karl Jürgen Bär, Valentin Markser

Friday, May 29th



07:30 Participants meet on the main entrance for the morning warm-up (sportswear required)

10:30 – 12:30 **SPORTS THERAPY IN DEPENDENCE DISORDERS**
Tobias Freyer (Freiburg, Germany)

SPORTS AND MOTOR ACTIVITY IN DEMENTIA
Karl Jürgen Bär (Jena, Germany)

SPORTS PSYCHIATRY: ISSUE, METHODS AND WORK OUT
Valentin Markser (Köln, Germany)

INTERNATIONAL HIGH PERFORMANCE SPORTS, TRAUMA AND CULTURAL BACKGROUND
Thomas Wenzel (Wien, Austria)

14:00 – 15:30 **SPORTS AND PHYSIOTHERAPY IN PSYCHIATRIC DISORDERS**
Case presentation and discussion

15:30 – 16:00 **Break**

16:00 – 17:30 **MENTAL HEALTH IN HIGH PERFORMANCE SPORTS**
Case presentation and discussion

1. THERAPEUTIC EFFICACY OF LAMOTRIGINE IN A PATIENT WITH BORDERLINE PERSONALITY DISORDER AND DEPRESSION EPISODES: A CASE REPORT

Arsova S., Manusheva N., Bajraktarov S.
University clinic of psychiatry Skopje Macedonia, Republic of Macedonia

2. THE PRESENCE OF CHRONIC PAIN IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND ITS INTERCORRELATION

Batinic B., Nesvanulica J., Stankovic I.
Clinical Center of Serbia, Clinic of Psychiatry, Belgrade, Serbia

3. WWOX MAY BE RELATED WITH SLEEPLESSNESS SYMPTOM OF BIPOLAR MANIA: A GENOME-WIDE ASSOCIATION STUDY

Chul-Hyun C., Heon-Jeong L., Leen K.
Korea University College of Medicine, Seoul, South Korea

4. SEXUAL ORGANIZATION OF THE BRAIN: NEURODEVELOPMENT, GENDER DIFFERENCES AND RELATION TO GENDER IDENTITY DISORDER

Duišin D., Batinić B., Barišić J.
Clinic of Psychiatry, Clinical Centre of Serbia, Belgrade, Serbia

5. THE EFFECT OF SUPPORT GROUP THERAPY ON PARENTALLY BEREAVED ADOLESCENTS: A RANDOMIZED CONTROLLED TRIAL

Elkeshishi H.E., Abuhegazy H.
El-Menia university, faculty of arts, Al-Azhar university, faculty of medicine, Cairo, Egypt

6. PROBABILITY DISTRIBUTION OF R-R INTERVALS DURING SLEEP IN NORMAL AND OSA CHILDREN

Eui-Joong K.¹, Young Min A.¹, Jong Won K.²
¹EMC Eulji University School of Medicine, Seoul, Republic of Korea
²Woolcock Institute for Medical Research, Seoul, Republic of Korea

7. ALTERNATIVE MEDICINE TREATMENTS OF PAIN

Greš A., Radovančević Lj.
Croatian Association for Patients Rights, Zagreb, Croatia

8. BODY AND SECONDARY GAIN

Greš A., Esapović Greš N.
Croatian Association for Patients Rights, Psychiatry Clinic- KBC Zagreb, Croatia

9. WHAT A CHILD AND ADOLESCENT MEET IN CONTEMPORARY SOCIETY

Greš A., Radovančević Lj.
Croatian Association for Patients Rights, Zagreb, Croatia

10. CORRELATION OF NOCTURNAL BRAIN ACTIVITY TO DAYTIME PVT PERFORMANCE IN OSA PATIENTS: A PILOT STUDY

HongBeom S.
KoSleep Center, South Korea

11. AN OVERVIEW OF THE REASONS FOR THE MEASURE OF HOSPITAL FORENSIC COMPULSORY TREATMENT FOR PATIENTS AT THE SLOVENIAN UNIT OF FORENSIC PSYCHIATRY (UFP) AND THE APPROACHES TO THEIR FURTHER CARE AFTER RELE

Koprivsek J., Celofiga A.
University Medical Centre Maribor, Slovenia

12. CASE REPORT OF THE DIAGNOSTIC ROLE OF ELECTROENCEPHALOGRAPHY IN DEMENTIA

Manusheva N., Arsova S., Bajraktarov S.
University clinic of psychiatry Skopje Macedonia, Republic of Macedonia

13. ARIPIRAZOLE IN BIPOLAR DISORDER: A META-ANALYSIS OF EFFICACY AND SAFETY IN RANDOMIZED CONTROLLED TRIALS AND OBSERVATIONAL STUDIES

Meduri M., Baglivo V., Brambilla P.
Azienda Ospedaliero-Universitaria Santa Maria della Misericordia, Udine, Italy

14. THE NECESSITY FOR ANTIDEPRESSANTS IN THE ELDERLY

Milosavljevik P.
Institute of Gerontology "13 November", Skopje, Republic of Macedonia

15. TIME PERSPECTIVE IN PSYCHODRAMA PSYCHOTHERAPY GROUP

Mindoljević Drakulić A.
Faculty of Teacher Education University of Zagreb, Croatia

16. EPIDEMIOLOGICAL FEATURES OF ACUTE ALCOHOLIC POISONING IN CHILDREN (2000-2010) POSTER PRESENTATION

Močenić I., Močenić D., Jašić M., Gazibara I., Mladinov O.
General Hospital Pula, Croatia

17. PREVALENCE OF POSTPARTUM DEPRESSION IN INPATIENTS HOSPITALIZED OVER TWO YEAR PERIOD – IN CLINIC OF GYNECOLOGY AND OBSTETRICS IN PRISHTINA

Obertinca B., Ibishi N., Paqarada M.
University Clinical Center of Kosovo, Prishtina, Kosovo

18. TOBACCO USING AND IT'S ASSOCIATION WITH POST PARTUM DEPRESSION-IN INPATIENTS HOSPITALIZED OVER TWO YEAR PERIOD IN CLINIC OF GYNECOLOGY AND OBSTETRICS-PRISHTINA

Obertinca B., Ibishi N., Paqarada M.
University Clinical Center of Kosovo, Prishtina, Kosovo

19. COMT MODULATES WORKING MEMORY AND IMPULSIVITY CONTROL IN BIPOLAR DISORDER

Piccin S., Bonivento C., Fabbro D., Marinelli V., Bell
University of Udine, Italy

20. A RISK ASSESSMENT SCORE TO QUANTIFY AUTONOMIC CHANGES IN PATIENTS SUFFERING FROM SCHIZOPHRENIA

Refisch A., Bär K.J., Schulz S.
Jena University Hospital, Germany

21. ALTERATIONS IN NEURAL REWARD PROCESSING IN EUTHYMIC PATIENTS WITH BIPOLAR DISORDER

Schreiter S., Spengler S.
Charité Universitätsmedizin Berlin, Germany

22. NEW FINDINGS ON ALCOHOL RELATED BRAIN DAMAGE

Šitum S., Uzelac G., Caratan S., Todorić Laidlaw I., Orešković A., Filipčić I.
Psychiatric Hospital "Sveti Ivan", Zagreb, Croatia

23. DEPRESSION IN PATIENTS ON DIALYSIS

Uglešić B., Lasić D., Vujnović Z.,
University Hospital Centre Split, Croatia

24. AN EXTREME TARDIVE DYSTONIA DUE TO THE NEUROLEPTIC THERAPY

Vitorovič S., Velikonja I., Vučko Miklavčič I., Kores Plesničar B.
University Psychiatric Clinic, Ljubljana, Slovenia

POSTERS NEUROLOGY

25. THE COMT VAL158MET POLYMORPHISM MODULATES THE ASSOCIATION BETWEEN COGNITIVE PERFORMANCES AND WHITE MATTER MICROSTRUCTURE IN A SAMPLE OF SCHIZOPHRENIC PATIENTS

Aggio V., Poletti S., Bolettini I., Mazza E., Cavallaro R., Benedetti F.
Scientific Institute and University Vita-Salute San Raffaele, Milano, Italy

26. NEUROPATHIC AND CHRONIC PAIN OUTCOMES FOLLOWING CAESAREAN SECTION: A COMPARATIVE STUDY

Belci D., Stark M., Di Renzo G.C., Zoričić D., Belci M.
General Hospital Pula, Croatia

27. CLOCK GENES ASSOCIATE WITH WHITE MATTER INTEGRITY IN DEPRESSED BIPOLAR PATIENTS: A TRACT-BASED SPATIAL STATISTICS STUDY

Bollettini I., Melloni Elisa M.T., Aggio V., Poletti S., Vai B., Dallaspezia S., Benedetti F.
Scientific Institute and University Vita-Salute San Raffaele, Milan, Italy

28. INTRACEREBRAL HEMORRHAGE AND ATRIAL FIBRILLATION

Budincevic H., Marcinko Budincevic A., Meter M., Saleh C., Bielen I., Demarin V.
Sveti Duh University Hospital, Zagreb, Croatia

29. EFFECTIVE CONNECTIVITY ON NEURAL RESPONSE TO EMOTIONAL PROCESSING IN BIPOLAR DISORDERS IS INFLUENCED BY THE INTERACTION BETWEEN LITHIUM AND GSK-3

Bulgarelli C., Vai B., Aggio V., Poletti S., Bollettini I., Benedetti F.
Institute and University Vita-Salute San Raffaele, Milan, Italy

30. THE EFFECTS OF TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS) ON PAIN IN SPINAL CORD INJURED PATIENTS.

Cortese A.M., Nowicky A., Belci M.
Imperial College Healthcare NHS trust, London, United Kingdom

31. FATIGUE IN MULTIPLE SCLEROSIS PATIENTS

Časar Rovazdi M., Vidović V., Kraml O., Bašić Kes V.
Special Hospital for Medical Rehabilitation Lipik, Croatia

32. NEUROPATHIC PAIN IN PATIENTS WITH LUMBOISCHIALGIA

Časar Rovazdi M., Vidović V., Rendulić Slivar S.
Special hospital for medical rehabilitation Lipik, Croatia

33. THE QUALITY OF LIFE IN PATIENTS WITH DIABETIC POLYNEUROPATHY

Dermanovic Dobrota V., Prkacin I., Dobrota S., Hrabac P., Lukinovic- Skudar V., Basic Kes V.
Clinical Hospital Merkur University Clinic Vuk Vrhovac, Zagreb, Croatia

34. THE PARIETAL LOBE IN BIPOLAR DISORDER: A CROSS-SECTIONAL AND LONGITUDINAL STUDY USING STRUCTURAL MRI

Ferro A., Bonivento C., Perlini C., Dusi N., Rambaldelli G., Bellani M., Marinelli V., Crespo-Facorro B., Brambilla P.
University of Udine, Department of Experimental and Clinical Medical Sciences, Udine, Italy

35. LATE-ONSET CASE OF RASMUSSEN ENCEPHALITIS – A CASE REPORT

Friedrich L., Sicaja G., Sruk A., Budincevic H., Bielen I.
Sveti Duh University Hospital, Zagreb, Croatia

36. PNES IN PATIENTS WITH EPILEPTIC SEIZURES

Gashoska M., Atanasovski P., Miftari V.
PHO University clinic of neurology, Skopje, Macedonia

37. MANAGEMENT OF PATIENT WITH RIGHT COMMON CAROTID ARTERY OCCLUSION AND LEFT INTERNAL CAROTID ARTERY STENOSIS: CASE REPORT

Govori V., Hundozi Z., Shala A.
University Clinical Center of Kosovo, Prishtina, Kosovo

38. CAROTID PLAQUE ECHOGENICITY IN PREDICTING SYMPTOMS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Jashari F., Ibrahim P., Henein M.
Umeå University, Public Health and Clinical Medicine, Umeå, Sweden

39. CEREBRAL MATTER ATTACKED BY EPILEPTIC ATTACKS SECONDARY TO CEREBRAL VASCULAR ACCIDENTS CASES

Jashari R., Jashari F., Koliqi-Lila R.
Medical Schol in Prishtina, Kosovo

40. CORTICAL AND SUBCORTICAL LESIONS ARE MOST FREQUENTLY ASSOCIATED WITH EPILEPSY AFTER STROKE

Jashari R., Jashari F., Koliqi-Lila R.
Medical Schol in Prishtina, Clinic for Neurology in Prishtina, Kosovo

41. TYPES OF EPILEPTIC ATTACKS TRIGGERED BY CEREBRAL VASCULAR ACCIDENTS

Jashari R., Rakacolli M., Lila G.
Medical Schol in Prishtina, Kosovo

42. MELKERSSON -ROSENTHAL SYNDROME

Kabashi M., Kukaj V., Pushka M., Govori V., Beqiri S.
University Clinical Centre of Kosovo, Prishtina, Kosovo

43. IDENTITY IN LIGHT OF INTEGRATIVE THERAPY AS A DISPOSITION FOR THE CONSTRUCTION OF NEW NEURAL PATHWAYS

Kapuralin T.
St. Stanislav Institution, Pula, Croatia

44. RESTLESS LEGS SYNDROME AND PERIODIC LIMB MOVEMENTS IN ACUTE STROKE PATIENTS WITH SLEEP APNEA

Kojić B., Sinanović O., Burina A., Imamović K., Vidović M.
University Clinical Center Tuzla, Medical school, University of Tuzla, Bosnia and Herzegovina

45. INTIMA-MEDIA CAROTID MEASUREMENTS IN PATIENTS WITH BILATERAL DISEASE

Lila G., Koliqi R., Jashari F.
University Clinical Centre of Kosovo, Prishtina, Kosovo

46. WHITE MATTER MICROSTRUCTURE PREDICTS RESPONSE TO CHRONOTHERAPEUTIC TREATMENT IN BIPOLAR DEPRESSION

Mazza E., Bollettini I., Poletti S., Locatelli C., Benedetti F.
Scientific Institute and University Vita-Salute San Raffaele, Milano, Italy

47. IS THE TEMPORAL STABILITY OF OBSESSIVE COMPULSIVE SYMPTOM DIMENSIONS INFLUENCED BY CLINICAL AND GENETIC CONTRIBUTIONS? A LIFETIME RETROSPECTIVE STUDY

Mazza M., Dallspezia S., Smeraldi E., Benedetti F.
Scientific Institute and University Vita-Salute San Raffaele, Milan, Italy

48. INFLUENCE OF ADVERSE CHILDHOOD EXPERIENCE ON GRAY MATTER VOLUME IN MAJOR PSYCHOSIS COMPARED TO HEALTHY CONTROLS

Melloni Elisa M.T., Gallo M., Poletti S., Bollettini I., Vai B., Aggio V., Benedetti F.
Scientific Institute and University Vita-Salute San Raffaele, Milano, Italy

49. STRUCTURAL CHANGES OF RAPHE NUCLEI IN DEPRESSION ASSOCIATED WITH PARKINSON'S DISEASE DETECTED BY TRANSCRANIAL SONOGRAPHY AND DIFFUSION TENSOR IMAGING

Mijajlović M., S. Kostić V.

Clinical Center of Serbia and School of Medicine, University of Belgrade, Serbia

50. COGNITIVE DYSFUNCTIONS IN ASEPTIC MENINGITIS CAUSED BY THE ECHO VIRUS – CASE REPORT

Petković D., Vuković B., Galić S., Andrić Z.

The County Hospital in Požega, Croatia

51. ANTIDEPRESSANT TREATMENT WITH TOTAL SLEEP DEPRIVATION INDUCES CHANGES IN WHITE MATTER MICROSTRUCTURE IN BIPOLAR DISORDER

Poletti S., Bollettini I., Melloni E., Dallspezia S., Benedetti F.

Scientific Institute and University Vita-Salute San Raffaele, Milano, Italy

52. MISLEADING AND SUCCESSFUL PRESYMPTOMATIC DIAGNOSIS OF WILSON DISEASE

Podskarbi T., Shin Y.

Molecular Genetics and Metabolism Laboratory, Munich, Germany

53. CLINICALLY ISOLATED SYNDROME-CASE REPORT

Serafimova K., Milosavljević P., Petkovska-Boshkova T.,

Clinic of neurology, Skopje, Macedonia

54. SPEECH LANGUAGE THERAPY IN GLOBAL APHASIA WITHOUT HEMIPARESIS

Shehu E., Gjerci S., Shehu E.

Regional hospital of Durres, Albania

55. THE PREVALENCE OF COGNITIVE DISORDERS IN STROKE PATIENTS IN THE NEUROLOGY CLINIC OF REGIONAL HOSPITAL OF DURRES

Shehu E., Gjerci S., Shehu E.

Regional hospital of Durres, Albania

56. EFFECT OF COMT POLYMORPHISM ON SUBCORTICAL VOLUMES IN SCHIZOPHRENIA

Spangaro M., Bollettini I., Poletti S., Mazza E., Cavallaro R., Benedetti F.

Scientific Institute and University Vita-Salute San Raffaele, Milan, Italy

57. INTRATHECAL BACLOFEN PUMP THERAPY IN SPINAL CORD INJURY PATIENTS: LONG-TERM DOSAGE EVALUATION

Stigliano S., Santilli V., Belci M.

Policlinico Umberto I “La Sapienza” in Rome, Italy

58. PERSISTENT SOMATOFORM PAIN DISORDER VS CHRONIC POSTOPERATIVE HEADACHE

Šumski I., Knez Turčinović M., Marinić R., Cigrovski A.

Neuropsychiatric hospital “Dr. I. Barbot”, Popovača, Croatia

59. STROKE POST ARTERITIS TB OR BRAIN INFECTION?

Trifan F., Vatu M., Stemate C.

University of Medicine and Pharmacy, Neurology Clinical Hospital, Craiova, Romania

60. FRONTO-LIMBIC NEURAL RESPONSE AND CONNECTIVITY PREDICT THE ANTIDEPRESSANT EFFECT OF CHRONOTHERAPEUTICS IN BIPOLAR DEPRESSION

Vai B., Poletti S., Bulgarelli C., Bollettini I., Smeraldi E., Colombo C., Benedetti F.

IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milano, Italy

61. PREGNANCY AND LABOR IN MULTIPLE SCLEROSIS: EXPERIENCES FROM TUZLA CANTON (BOSNIA AND HERZEGOVINA)

Vidović M., Burina A., Sinanović O., Zukić S.

University Clinical Center Tuzla, School of Medicine of University Tuzla, Bosnia and Herzegovina

62. DEPRESSIVE SYNDROME IN PATIENTS WITH CHRONIC BACK PAIN

Vidović V., Časar Rovazdi M., Kraml O., Rendulić Slivar S.

Special hospital for medical rehabilitation Lipik, Croatia

63. SELF-PERCEIVED COGNITIVE DYSFUNCTION IN MULTIPLE SCLEROSIS PATIENTS

Vidović V., Časar Rovazdi M., Kraml O., Bašić Kes V.

Special Hospital for Medical Rehabilitation Lipik, Croatia

64. OSTEOPONTIN GENE AND CLINICAL COURSE OF MULTIPLE SCLEROSIS IN A POLISH POPULATION

Wender M., Michałowska - Wender G., Biernacka-Łukanty J., Raczak B., Sławomir

Medical Research Centre, Polish Academy of Sciences, Poznań, Poland

65. FREQUENCY AND TYPE OF SLEEP DISTURBANCES IN PARKINSON'S DISEASE PATIENTS

Zonić L., Sinanović O., Vidović M.

University Clinical Center Tuzla, School of Medicine of University Tuzla, Bosnia and Herzegovina

66. SENSORY FIBERS IN MARTIN-GRUBER ANASTOMOSIS: A CASE REPORT

Zukić S., Sinanović O., Pirić N., Hodžić R., Burina A.

University Clinical Center Tuzla, School of Medicine of University Tuzla, Bosnia and Herzegovina

All lectures and posters will be published in the Abstract book of the International Neuropsychiatric Congress, ISSN 1849-7438, electronic edition (www.pula-cong.com)

POSTERS PRESENTATIONS

Psychiatry: Friday, May 29th, 12:00 – 13:00 – (PP Histria – Bianca Istriana)
 Neurology: Friday, May 29th, 16:30 – 18:00 – (PP Histria – Bianca Istriana)

During the indicated time of the poster session there will be a poster guided tour selecting best posters that will receive the Best Poster Prizes! The poster guided tour requires a presence of one of the poster authors or it will not be considered as a prize nominees. Poster dimensions are 90 (width) x 120 (height) cm. Posters can be mounted from 13:00 Wednesday, May 27th and can stay exhibited until Saturday, May 30th.

CONGRESS VENUE

Hotel Park Plaza Histria, Pula, Croatia
 Congress Centre

OFFICIAL LANGUAGE

The official language is English.

REGISTRATION FEE

PARTICIPANTS	Early Bird Until March 8 th	Regular From March 9 th	Late & On-site From May 10 th
High Income Country Delegate	300 Eur	400 Eur	500 Eur
Low / Middle / Upper Middle Income County*	150 Eur	200 Eur	250 Eur
Trainees/Students**	150 Eur	150 Eur	150 Eur
Accompanying persons***	100 Eur	100 Eur	100 Eur

* Low, Middle and Upper Middle Income Countries are defined according to the World Bank Country Classification

** Trainees and Students must submit an official supportive letter from the institution, signed by the head of the department confirming your status, or a valid status ID card must accompany the registration.

*** Each delegate can register one accompanying person. Accompanying persons do not follow the scientific program of the Congress. They are welcome to join the social program of the 55th INPC.

PLEASE NOTE: VAT (25%) is included in the Registration Fees

Prices in Kuna will be charged at a middle rate of the Croatian National Bank on the day of payment.

Registration fee includes

- Admission to the all Congress Sessions, Schools and Courses and the Exhibition Area
- Refreshments as indicated in the program
- Welcome Reception and other Social events

ON-SITE PAYMENT METHODS

Payment of Registration fees can be made:

- in Cash in Euro or Croatian Kuna
- by Credit Card (Visa or MasterCard)

REGISTRATION DESK

Working hours

Wednesday 14:00 – 20:00
 Thursday 8:00 – 18:00
 Friday 8:00 – 19:00
 Saturday 8:00 – 13:00

TECHNICAL ORGANIZER

AMALIA Ltd., Jordanovac 117, 10 000 Zagreb, Croatia

SOCIAL PROGRAM

Wednesday, **May 27th, 2015** 19:30 Welcome reception – Park Plaza Histria
 Welcoming drink and traditional Istrian folk dances performed by Artistic group “Mendula” from Medulin

Friday, **May 29th, 2015** 20:00 Farewell cocktail – Istrian eno-gastronomy evening

INPC SECRETARIAT

Society for Neuropsychiatry
 10000 Zagreb, Croatia
 E-mail: info@pula-cong.com
 Web: www.pula-cong.com

SPONSORS & SUPPORTERS

We wish to express our gratitude to the following companies and institutions, who, through their generosity, have helped to make this congress possible:



Ministarstvo znanosti, obrazovanja i sporta
Ministry of Science, Education and Sport



City of Pula



City of Graz



ISTARSKA REGIONE
ŽUPANIJA ISTRIANA



Hrvatska turistička zajednica
Croatian National Tourist Board



Oblikovanje i prijelom / Design & Layout: AXIS-DESIGN d.o.o., Zagreb / 01 232 0202 / design@axis-design.hr

Jedanput dnevno

AUBAGIO®
(teriflunomid) 14mg
filmom obložene
tablete



**JEDANPUT NA DAN PERORALNA TERAPIJA
za liječenje odraslih bolesnika s relapsno-remitirajućom
MULTIPLOM SKLEROZOM**

- ~ **Djelotvornost** dokazana u kliničkim studijama na > 2700 bolesnika^{1,2,3,4}
- ~ **Sigurnosni profil** dosljedan kroz provedene kliničke studije⁵
- ~ **Selektivan mehanizam djelovanja** koji čuva imunološki sustav^{6,7}
- ~ **Praktično doziranje:** jedna tableta, jednom dnevno, u bilo koje doba dana⁶

SAMO ZA ZDRAVSTVENE RADNIKE

Reference:

1. O'Connor P, Wolinsky JS, Confavreux C, et al; TEMSO Trial Group. Randomized trial of oral teriflunomid for relapsing multiple sclerosis. *N Engl J Med*. 2011;365(14):1293-1303. 2. Kappos L, Comi G, Confavreux C, et al. The efficacy and safety of teriflunomid in patients with relapsing MS: results from TOWER, a phase III placebo-controlled study. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 10-13, 2012; Lyon, France. Oral presentation 0153.
3. O'Connor PW, Li D, Freedman MS, et al; Teriflunomid Multiple Sclerosis Trial Group. A phase II study of the safety and efficacy of teriflunomid in multiple sclerosis with relapses. *Neurology*. 2006;66(6):894-900. 4. Vermersch P, Czlownowska A, Grimaldi LM, et al; TENERE Trial Group. Teriflunomid versus subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomised, controlled phase 3 trial. *Mult Scler*. 2013. 5. Leist TP, Freedman MS, Kappos L, et al. Pooled safety data from three placebo-controlled teriflunomid studies. Poster presented at: 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 2-5, 2013; Copenhagen, Denmark. Poster P633. 6. **Sažetak opisa svojstva lijeka AUBAGIO.** Dostupno na <http://www.ema.europa.eu/ema>. 7. Clausen MC, Korn T. Immune mechanisms of new therapeutic strategies in MS-teriflunomid. *Clin Immunol*. 2011;142(1):49-56.

SVAKAKI SA ŽETAK OPISA SVOJSTVA LIJEKA - 1. NAZIV LIJEKA I SAŽETAK: Aubagio 14 mg filmom obložene tablete. Jedna filmom obložena tableta sadrži 14 mg teriflunomida. **2. TERAPIJSKI INDIKACIJE:** Za liječenje odraslih bolesnika s relapsno-remitirajućom multiplom sklerozom (MS). **3. DOZIRANJE I NAČIN PRIMJENE:** Preporučena doza lijeka AUBAGIO® 14 mg je jedanput na dan. Tablete se moraju progutati cijele s malom količinom vode. Stanje primjenjivosti na oprez u bolesnika u dobi od 65 godina i starijih zbog nedostataka podataka o sigurnosti i djelotvornosti. Običnoje najbolje funkcioniranje u bolesnika s blagim, umjerenim ili teškim običnim bubrežnim funkcijama koje se ne liječe dijalizom. Bolesnici s teškim običnim bubrežnim funkcijama koje se liječe dijalizom nisu ispitivani. Teriflunomid je kontraindiciran u trudnoći. Teriflunomid je kontraindiciran u bolesnika s teškim običnim bubrežnim funkcijama koje se ne liječe dijalizom. Bolesnici s teškim običnim bubrežnim funkcijama koje se liječe dijalizom nisu ispitivani. Teriflunomid je kontraindiciran u bolesnika s teškim običnim bubrežnim funkcijama koje se ne liječe dijalizom. Bolesnici s teškim običnim bubrežnim funkcijama koje se liječe dijalizom nisu ispitivani. **4. KONTRAINDIKACIJE:** Preporučena doza lijeka AUBAGIO® 14 mg je jedanput na dan. Tablete se moraju progutati cijele s malom količinom vode. Stanje primjenjivosti na oprez u bolesnika u dobi od 65 godina i starijih zbog nedostataka podataka o sigurnosti i djelotvornosti. Običnoje najbolje funkcioniranje u bolesnika s blagim, umjerenim ili teškim običnim bubrežnim funkcijama koje se ne liječe dijalizom. Bolesnici s teškim običnim bubrežnim funkcijama koje se liječe dijalizom nisu ispitivani. Teriflunomid je kontraindiciran u trudnoći. Teriflunomid je kontraindiciran u bolesnika s teškim običnim bubrežnim funkcijama koje se ne liječe dijalizom. Bolesnici s teškim običnim bubrežnim funkcijama koje se liječe dijalizom nisu ispitivani. **5. POSEBNA UPREZORANJA I NAČIN OPREZA PRI UPORABI:** Prije liječenja teriflunomidom treba provesti krvni test, a zatim amiotransferazu (ALT/SGPT), kompletnu krvnu sliku, krvni test, alanin aminotransferazu (ALT/SGPT), kompletnu krvnu sliku i test na trudnoću. **6. INTERAKCIJE S DRUGIM LIJEKOVIMA I DRUGI KLINIKI INTERAKCIJE:** Farmakološke interakcije: Liječenje teriflunomidom treba izbjegavati s lijekovima koji sadrže teriflunomid i s lijekovima koji sadrže teriflunomid. **7. PUDORNOŠĆA I DOJENJE:** Prije liječenja teriflunomidom treba provesti krvni test, a zatim amiotransferazu (ALT/SGPT), kompletnu krvnu sliku, krvni test, alanin aminotransferazu (ALT/SGPT), kompletnu krvnu sliku i test na trudnoću. **8. INTERAKCIJE S DRUGIM LIJEKOVIMA I DRUGI KLINIKI INTERAKCIJE:** Farmakološke interakcije: Liječenje teriflunomidom treba izbjegavati s lijekovima koji sadrže teriflunomid i s lijekovima koji sadrže teriflunomid. **9. OPREZ:** Prije liječenja teriflunomidom treba provesti krvni test, a zatim amiotransferazu (ALT/SGPT), kompletnu krvnu sliku, krvni test, alanin aminotransferazu (ALT/SGPT), kompletnu krvnu sliku i test na trudnoću. **10. PREDOZIRANJE:** Nema iskustva s prodavanjem ili trovanjem teriflunomidom u ljudi. Teriflunomid u dozi od 70 mg na dan primjenjivan je tijekom najviše 14 dana u završnoj ispitivanju. Nasuprot su bile slučajne ozbiljne nuspojave teriflunomida u bolesnika s multiplom sklerozom. **11. FARMAKODINAMIKA I FARMAKOKINETIKA:** Farmakodinamika: Teriflunomid je selektivni inhibitor imunološkog sustava. **12. NASTAVAK DOJAVLJIVANJA:** Sanofi-aventis group, 54 rue La Boétie, F-75008 Paris, France. **13. BROJEVI DOJAVLJIVANJA ZA STAVLJANJE GOTOVOG LIJEKA U PROMET:** EU/1/13/83/001-005. **14. NAČIN I MJEŠTO DOJAVLJIVANJA:** Na receipt, u ljekarni. Detaljnije informacije o ovom lijeku dostupne su na web stranici Evropske agencije za lijekove <http://www.ema.europa.eu/>.

Ovo je skraćeni Sažetak opisa svojstva lijeka te sukladno Pravilniku o načinu označavanja o lijekovima homeopatskim proizvodima (Bandere-Nowie broj 118/09) molimo prije propisivanja lijeka Aubagio pročitati zadnji odobreni Sažetak opisa svojstva lijeka i Uputa za lijekove.



sanofi-aventis Croatia d.o.o. | Heinzelova 70 | 10000 Zagreb | Croatia. HR.AUB.15.01.01.

ZYPADHERA¹

Dugodjelujući oblik olanzapina

Učinkovitost slična kao i kod oralne primjene olanzapina

Brzi početak djelovanja - postiže se već unutar 1 tjedna

Nije potrebna dodatna oralna terapija olanzapinom

Mogućnost fleksibilnog 2 i 4 tjednog doziranja

Ne čuva se u hladnjaku

Profil nuspojava odgovara onom kod oralnog olanzapina

s iznimkom post injekcijskog sindroma

Referenca: 1. Sažetak opisa svojstava lijeka ZypAdhera

ZYPAdheraTM
Olanzapin prašak i otapalo za suspenziju
za injekciju s produljenim oslobađanjem

ZYPADHERA 210 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem (olanzapin) ZYPADHERA 300 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem (olanzapin) ZYPADHERA 405 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem (olanzapin) Broj odobrenja zastavljanje lijeka u promet: EU/1/08/479/001, EU/1/08/479/002, EU/1/08/479/003 Način i mjesto izdavanja lijeka: Lijek se izdaje na recept.

Predstavnik nositelj odobrenja: ELI LILLY HRVATSKA d.o.o., Ulica grada Vukovara 269 G, 10 000 Zagreb

Terapijske indikacije: Terapija održavanja u odraslih bolesnika sa shizofrenijom koji su odgovarajuće stabilizirani oralnim oblikom olanzapina tijekom liječenja akutne faze. **Kontraindikacije:** Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari, Bolesnici s poznatim rizikom od glaukoma uskoj kuta. **Posebna upozorenja i posebne mjere opreza pri uporabi:** Primjena u bolesnika u stanju akutne agitiranosti ili teške psihoze. ZYPADHERA se ne smije primjenjivati u liječenju bolesnika sa shizofrenijom koji su u stanju akutne agitiranosti ili teške psihoze i kod kojih je potrebna trenutna kontrola simptoma. Postinjekcijski sindrom Tijekom kliničkih ispitivanja prije puštanja lijeka u promet nakon injekcije lijeka ZYPADHERA u bolesnika su prijavljene nuspojave karakterizirane znakovima i simptomima koji odgovaraju onima koji se javljaju kod predoziranja olanzapinom. **Nuspojave na mjestu primjene** Najčešće prijavljivane nuspojave na mjestu primjene injekcije bila je bol. **Pshoha povezana s demencijom i /ili poremećaji ponašanja** Primjena olanzapina ne preporučuje se u bolesnika s psihozom povezanom s demencijom i/ili poremećajima ponašanja zbog povećane smrtnosti i rizika od cerebrovaskularnog incidenta. **Parkinsonova bolest** Ne preporučuje se primjena olanzapina u liječenju psihoze povezane s agonistima dopamina u bolesnika s Parkinsonovom bolešću. **Malig. neuroleptički sindrom (MNS)** Ako bolesnik razvije znakove i simptome koji upućuju na MNS ili druge visoku vjerojatnost neispravnog uzroka bez dodatnih kliničkih manifestacija MNS-a, mora se odmah prekinuti primjena svih antipsihotika, uključujući olanzapin. **Hiperglikemija i dijabetes** Hiperglikemija i/ili pojava odnosno egzacerbacija dijabetesa, ponekad povezano s ketoacidom ili komom, uključujući i neke smrtno slučajevne, manje je često prijavljivane nuspojave. **Općenito djelovanje na SŽS** Većina za primarne učinke olanzapina na SŽS, mora se s oprezom istodobno primjenjivati s drugim lijekovima koji djeluju centralno i s alkoholom. **Znenadna srčana smrt** U izvješćima o olanzapinu nakon stavljanja lijeka u promet zabilježeni su slučajevi iznenadne srčane smrti u bolesnika liječenih olanzapinom. **Trudnoća i dojenje** Ne postoje odgovarajuća i dobro kontrolirana ispitivanja s trudnicama. Bolesnice se mora savjetovati da obavijeste svog liječnika ako zatrudne ili namjeravaju zatrudnjeti tijekom liječenja olanzapinom. **Pedijatrijska populacija** Primjena olanzapina nije indicirana u liječenju djece i adolescenata. **Primjena u starijih bolesnika > 75 godina** Nisu dostupne informacije o primjeni lijeka ZYPADHERA u bolesnika starijih od 75 godina. **Prestanak liječenja** Kod naglog prestanka peroralne primjene olanzapina tijekom su prijavljeni (n= 0,01% i - 0,1%) akutni simptomi poput znojenja, nesanic, tremora, anksioznosti, mučnine ili povraćanja. **Nuspojave:** Kod primjene lijeka ZYPADHERA nastupile su nuspojave postinjekcijskog sindroma koje dovode do simptoma poput onih koji se javljaju kod predoziranja olanzapinom. Klinički znakovi i simptomi uključuju simptome sedacije (različitih stupnjeva težine; od blage do teške sedacije, tj. kome) i/ili delirija (uključujući konfuziju, dezorijentaciju, agitaciju, anksioznost i druga oštećenja kognitivnih funkcija). Od ostalih simptoma zabilježeni su ekstrapiramidni simptomi, dizurija, ataksija, agresija, omaglica, slabost, hipertenzija i kornuluzije. **Doziranje i način primjene: ISKLJUČIVO ZA INTRAMUSKULARNO PRIMJENJENJE. NE PRIMJENJIVATI INTRAVENSKI NITI SUPURATANO.** ZYPADHERA se smije davati samo u obliku duboke glutealne intramuskularne injekcije i to od strane zdravstvenoga djelatnika obučavane u korištenju odgovarajućih tehnika davanja injekcija i na mjestima gdje postoji mogućnost promatranja bolesnika nakon injekcije i gdje je moguće osigurati primjerenu medicinsku skrb u slučaju predoziranja. Nakon svake injekcije odgovarajuće osposobljeno osobe mora u zdravstvenoj ustanovi motriti bolesnika kroz najmanje 3 sata kako bi se uočila eventualna pojava znakova i simptoma koji se javljaju kod predoziranja olanzapinom. Neposredno prije otpusta iz zdravstvene ustanove mora se potvrditi da je bolesnik prisutan, orijentiran i da nema znakova ni simptoma predoziranja. **Važno:** Informacije pripremljene samo za zdravstvene radnike. Lijek ZypAdhera izdaje se na recept. Prije propisivanja lijeka ZypAdhera molimo pročitate zadnji odobreni Sažetak opisa svojstava lijeka i Uputu o lijeku. Detaljnije informacije o ovom lijeku i zadnji odobreni Sažetak opisa svojstava lijeka možete dobiti od Eli Lilly (Suisse) S.A. Predstavništva u RH na web stranici Europske agencije za lijekove: <http://www.ema.europa.eu>, tona web stranica Europske komisije: <http://ec.europa.eu/health/documents/community-register/html/all/register.htm>. Ovi promotivni materijali sadrže bitne podatke o lijeku koji su istovjetni cjelokupnom odobrenom sažetku svojstava lijeka te cjelokupnoj odobrenj uputi sakladno članku 15. Pravilnika o načinu oglašavanja o lijekovima i homeopatskim proizvodima („Narodne novine“ broj 118/2009, HRZVA000758/1), Rujan 2014.

Čiljna doza oralnog olanzapina	Preporučena početna doza ZYPADHERE	Doza održavanja nakon dva mjeseca liječenja lijekom ZYPADHERA
10 mg/dan	210 mg/2 tjedna ili 405 mg/4 tjedna	150 mg/2 tjedna ili 300 mg/4 tjedna
15 mg/dan	300 mg/2 tjedna	210 mg/2 tjedna ili 405 mg/4 tjedna
20 mg/dan	300 mg/2 tjedna	300 mg/2 tjedna

Eli Lilly (Suisse) S.A.
Predstavništvo u RH, Ulica grada Vukovara 269 G, 10 000 Zagreb,
Tel: +385 1 2350 999, Fax: +385 1 2305 670

Lilly